Article
Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.
Oncogene - 20 Jun 2013
Chell V, Balmanno K, Little A S, Wilson M, Andrews S, Blockley L, Hampson M, Gavine P R, Cook S J
Abstract excerpt
Fibroblast growth factor receptors (FGFRs) can act as driving oncoproteins in certain cancers, making them attractive drug targets. Here we have characterized tumour cell responses to two new inhibitors of FGFR1-3, AZ12908010 and the clinical candidate AZD4547, making comparisons with the well-characterized FGFR inhibitor PD173074. In a panel of 16 human tumour cell lines, the anti-proliferative activity of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.